Icagen (ICGN) Presented Data Found in Collaboration with Pfizer (PFE) to Identify Sodium Channel Modulators
More News related to ICGN
- Unusual 11 Mid-Day Movers 01/13: ROSG, ICGN, MRNA, AGEN Higher; FLDR, HEV, RSCR, AMFI Lower
- Icagen to Present at the JP Morgan Healthcare Conference
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Morning Movers 10/27: HPGP, HLND, TBAC, CTDC, PODD, HSII Higher; ICGN, AMFI, IBCP, CRI, SGMS, PVTB Lower
- After-Hours Movers 10/26: ENTR, UCTT, LULU, IVAC, TBAC Higher; ICGN, ZRAN, BIDU, WINN, LTD Lower
More News related to PFE
- Active equity option families in first 30 minutes: PFE, BAC, CSCO, AMZN, AAPL
- Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness
- Top 10 News Items 2/1-2/5: 9.7% Unemployment Rate Surprises the Market, Dow Breaks 10,000, But Recovers, Troubles at Toyota Continue
- Active equity option families in first 30 minutes: BAC F PFE AAPL
- QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Icagen, Inc. (NASDAQ: ICGN) today announced that data related to its collaboration with Pfizer (NYSE: PFE) focused on certain sodium channels for the treatment of pain and related conditions were presented in two poster presentations at the Neuroscience 2009 Annual Meeting sponsored by the Society for Neuroscience in Chicago, Illinois.
Icagen and Pfizer jointly presented data demonstrating progress in identifying subtype-selective modulators of the sodium channel Nav1.8. This channel is one of three sodium channel pain targets that form the basis of the collaboration. There are extensive preclinical data demonstrating a role for Nav1.8 in modulating pain. However, to date only limited examples of subtype-selective small molecule modulators of Nav1.8 have been described. In collaboration with Pfizer, Icagen presented pharmacokinetic and efficacy data for two novel modulators of this target. These orally bioavailable, use-dependent compounds have excellent in vitro profiles, impact nerve firing, are efficacious in models of inflammatory and neuropathic pain and have acceptable pharmacokinetic and drug-like properties. Overall these data provide further evidence for the feasibility of identifying selective Nav1.8 compounds as potential novel therapeutic agents for the treatment of pain.
"While sodium channel blockers have been used to treat pain for many years, currently available agents are not subtype-selective and therefore are limited by serious side effects," noted Douglas Krafte, Ph.D., VP Biology and Pharmacology at Icagen. "In collaboration with Pfizer, compounds which selectively inhibit one particular subtype of voltage-gated sodium channels, Nav1.8, have been characterized. By blocking only one subtype of these channels it should be possible to identify compounds which demonstrate efficacy in pain with an improved side effect profile as compared with existing therapies. We look forward to continuing this research program with Pfizer as we seek to identify novel clinical compounds for the treatment of pain and related disorders."
Related Categories
Corporate NewsStocks Mentioned
-0.03
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
